Royal Bank of Canada Increases Agios Pharmaceuticals (AGIO) Price Target to $91.00
Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective raised by stock analysts at Royal Bank of Canada to $91.00 in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would suggest a potential upside of 29.39% from the company’s previous close. The analysts noted that the move was a valuation call.
Several other equities analysts also recently issued reports on AGIO. SunTrust Banks reissued a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Credit Suisse Group upped their price objective on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Oppenheimer set a $83.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 17th. Cann reissued a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Finally, Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $77.64.
Agios Pharmaceuticals (NASDAQ AGIO) opened at $70.33 on Thursday. The stock has a market cap of $3,430.00, a P/E ratio of -11.22 and a beta of 1.83. Agios Pharmaceuticals has a one year low of $39.24 and a one year high of $76.02.
In other news, CEO David P. Schenkein sold 53,000 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total value of $3,877,480.00. Following the completion of the sale, the chief executive officer now owns 53,000 shares of the company’s stock, valued at $3,877,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Biller sold 2,146 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $62.69, for a total transaction of $134,532.74. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 80,130 shares of company stock worth $5,561,250. 5.43% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in AGIO. FMR LLC increased its position in shares of Agios Pharmaceuticals by 14.1% in the second quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Agios Pharmaceuticals by 23.8% in the second quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares in the last quarter. BlackRock Inc. increased its position in shares of Agios Pharmaceuticals by 23.5% in the second quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock worth $137,648,000 after acquiring an additional 508,306 shares in the last quarter. Alkeon Capital Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $30,489,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth $20,423,000. 94.32% of the stock is owned by institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.